According to the Zhitong Finance app, Honliv Health (09906) announced its mid-term performance in 2024, with a revenue of approximately 0.415 billion yuan, a year-on-year growth of 12.1%; gross profit of 71.621 million yuan, a year-on-year growth of 2.4%; the company's attributable profit in the period was 20.042 million yuan, a year-on-year decrease of 17.4%; basic and diluted earnings per share were 0.04 yuan.

In the period, the number of outpatient visits was 748.72, an increase of 5.9% year-on-year. The number of hospital admissions was 29,218, an increase of 5.8% year-on-year.